SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Relay Therapeutics Reports Smaller-Than-Estimated Q3 Loss, Sees Trial Enrollment Complete Mid-2027

Relay Therapeutics said it expects breast cancer trial enrollment to be complete in mid-2027.

RLAY

Related stories